P53, a tumor suppressor gene that is mutated and inactivated in the vast majority of cancers, has often been described as the "guardian of the genome" because of its protective effects against cancer.

In a recent perspective published in the journal Cell Death and Differentiation, researchers in France, Germany, and Sweden discussed the unique mutational spectrum of the transformation-related ...

The results of research headed by a team in the lab of Michael Sigal, MD, at the Max Delbrück Center and Charité—Universitätsmedizin Berlin, have shed new light on the role of the p53 tumor suppressor ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...

D.P. Lane, S. Benchimol, "p53: Oncogene or anti-oncogene?" Genes & Development, 4:1-8, 1990. David Lane (Cancer Research Campaign Laboratories, University of Dundee, Scotland): "Cancer is a multistep ...

TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...

Researchers in Class of 1942 Professor of Chemistry Matthew D. Shoulders' lab have uncovered a sinister hidden mechanism that ...

A genetic fault long believed to drive the development of esophageal cancer may in fact play a protective role early in the disease. This unexpected discovery could help doctors identify which ...